IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics. Its provides single-cell proteomics platform, which includes instruments, chip consumables and software, provides an end-to-end solution to reveal a view of protein function at an individual cellular level. The company also offers IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. It markets and sell its technology across the United States, Canada, the United Kingdom, Belgium, France, Czech Republic, Spain, Germany, Sweden, Italy, Israel, Ireland, Netherlands, Portugal, Switzerland, China, Taiwan, Singapore, Japan, Australia, and Korea. The company was incorporated in 2013 and is headquartered in Branford, Connecticut. IsoPlexis Corporation operates as a subsidiary of Bruker Cellular Analysis, Inc.